JP2025000630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025000630A5 JP2025000630A5 JP2024152009A JP2024152009A JP2025000630A5 JP 2025000630 A5 JP2025000630 A5 JP 2025000630A5 JP 2024152009 A JP2024152009 A JP 2024152009A JP 2024152009 A JP2024152009 A JP 2024152009A JP 2025000630 A5 JP2025000630 A5 JP 2025000630A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- mtor inhibitor
- carcinoma
- kras
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729228P | 2018-09-10 | 2018-09-10 | |
| US62/729,228 | 2018-09-10 | ||
| JP2021513318A JP2022500384A (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
| PCT/US2019/050240 WO2020055761A1 (en) | 2018-09-10 | 2019-09-09 | Combination therapies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513318A Division JP2022500384A (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025000630A JP2025000630A (ja) | 2025-01-07 |
| JP2025000630A5 true JP2025000630A5 (enExample) | 2025-06-05 |
Family
ID=69778030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513318A Pending JP2022500384A (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
| JP2024152009A Pending JP2025000630A (ja) | 2018-09-10 | 2024-09-04 | 組み合わせ療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513318A Pending JP2022500384A (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220040182A1 (enExample) |
| EP (1) | EP3849535A4 (enExample) |
| JP (2) | JP2022500384A (enExample) |
| AU (1) | AU2019338207B2 (enExample) |
| CA (1) | CA3111980A1 (enExample) |
| WO (1) | WO2020055761A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190624A1 (es) | 2016-07-12 | 2019-04-26 | Revolution Medicines Inc | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2 |
| CN117327075A (zh) | 2017-01-23 | 2024-01-02 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| EP3571189B1 (en) | 2017-01-23 | 2023-03-29 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
| EP3724189B1 (en) | 2017-12-15 | 2023-10-04 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| WO2020055760A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12336995B2 (en) * | 2018-09-10 | 2025-06-24 | Mirati Therapeutics, Inc. | Combination therapies |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CA3153456A1 (en) | 2019-10-02 | 2021-04-08 | Stefanie Fluckiger-Mangual | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN116194456B (zh) * | 2020-04-30 | 2025-08-29 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| EP4168002A1 (en) * | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| KR20230028798A (ko) | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| US20250340548A1 (en) | 2021-11-05 | 2025-11-06 | Frontier Medicines Corporation | Kras g12c inhibitors |
| CN116217591A (zh) * | 2021-12-02 | 2023-06-06 | 思路迪生物医药(上海)有限公司 | 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物 |
| EP4504203A1 (en) * | 2022-04-04 | 2025-02-12 | Sanofi | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329758B1 (en) | 1999-05-24 | 2008-02-12 | California Institute Of Technology | Imidazolidine-based metal carbene metathesis catalysts |
| KR20080078668A (ko) | 2005-11-17 | 2008-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | 융합된 바이사이클릭 ｍＴＯＲ 억제자 |
| KR101438245B1 (ko) | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US8785457B2 (en) | 2009-03-13 | 2014-07-22 | Cellzome Limited | Pyrimidine derivatives as mTOR inhibitors |
| EP2417138B1 (en) | 2009-04-09 | 2019-11-27 | Merck Sharp & Dohme Corp. | Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors |
| EP2525659B1 (en) | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| WO2011123524A2 (en) | 2010-03-31 | 2011-10-06 | Auspex Pharmaceutical, Inc. | Macrolide inhibitors of mtor |
| US20120107304A1 (en) * | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| CA2799764A1 (en) | 2010-05-19 | 2011-11-24 | Xcovery Holding Company, Llc. | Mtor selective kinase inhibitors |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| JP2013544828A (ja) | 2010-11-24 | 2013-12-19 | エクセリクシス， インク． | ｍＴＯＲの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法 |
| US20140163023A1 (en) | 2011-04-04 | 2014-06-12 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
| US8901142B2 (en) | 2011-07-26 | 2014-12-02 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds as mTOR inhibitors |
| RU2616619C2 (ru) | 2011-09-21 | 2017-04-18 | Селлзоум Лимитед | Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor |
| BR112014008241A2 (pt) | 2011-10-07 | 2017-04-18 | Cellzome Ltd | composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto |
| EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
| FR2986232B1 (fr) | 2012-01-26 | 2014-02-14 | Sanofi Sa | Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique |
| JP6441219B2 (ja) | 2012-08-06 | 2018-12-19 | ピットニー・ファーマシューティカルズ・ピーティーワイ・リミテッド | ｍＴＯＲ経路関連疾患を治療するための化合物 |
| DK2922872T3 (da) * | 2012-11-21 | 2019-01-02 | Janssen Biotech Inc | Bispecifikke egfr/c-met-antistoffer |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| CN112494653A (zh) * | 2015-02-05 | 2021-03-16 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| AU2015398613B2 (en) | 2015-06-15 | 2021-08-12 | Newsouth Innovations Pty Limited | Pharmaceutical combinations of organo-arsenoxide compounds and mTOR inhibitors |
| AU2017266911B2 (en) * | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
-
2019
- 2019-09-09 JP JP2021513318A patent/JP2022500384A/ja active Pending
- 2019-09-09 EP EP19859200.8A patent/EP3849535A4/en active Pending
- 2019-09-09 CA CA3111980A patent/CA3111980A1/en active Pending
- 2019-09-09 AU AU2019338207A patent/AU2019338207B2/en active Active
- 2019-09-09 WO PCT/US2019/050240 patent/WO2020055761A1/en not_active Ceased
- 2019-09-10 US US17/275,180 patent/US20220040182A1/en active Pending
-
2024
- 2024-09-04 JP JP2024152009A patent/JP2025000630A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000630A5 (enExample) | ||
| JP2025000632A5 (enExample) | ||
| JP2025000629A5 (enExample) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| CN102612365B (zh) | 用于强化dna损伤剂的检查点激酶1抑制剂 | |
| HRP20230377T1 (hr) | Inhibitori mutacije kras g12c | |
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| JPWO2021061749A5 (enExample) | ||
| JP2019516718A5 (enExample) | ||
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| JPWO2020118066A5 (enExample) | ||
| JPWO2023001141A5 (enExample) | ||
| JPWO2023059597A5 (enExample) | ||
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| JPWO2020055755A5 (enExample) | ||
| JPWO2020055761A5 (enExample) | ||
| CN102256603B (zh) | 用于在治疗中增加凋亡的有丝分裂抑制剂 | |
| JPWO2023059596A5 (enExample) | ||
| JPWO2023059594A5 (enExample) | ||
| JPWO2020247475A5 (enExample) | ||
| JPWO2020055758A5 (enExample) | ||
| JPWO2022056307A5 (enExample) | ||
| JPWO2023059600A5 (enExample) | ||
| JPWO2022251193A5 (enExample) | ||
| JPWO2023059598A5 (enExample) |